B. Riley Estimates Exagen's Q3 Earnings (NASDAQ:XGN)

Key Points

• B. Riley forecasts Exagen's Q3 2025 earnings to be at ($0.12) per share, maintaining a "Strong-Buy" rating on the stock.
• Exagen's consensus estimate for full-year earnings is ($0.88) per share, with various future earnings projections indicating improving trends through FY2026.
• Exagen has attracted institutional interest, with 75.25% of its stock currently owned by hedge funds and other institutional investors.

Exagen Inc. (NASDAQ:XGN - Free Report) - Equities research analysts at B. Riley issued their Q3 2025 EPS estimates for shares of Exagen in a research note issued on Wednesday, September 10th. B. Riley analyst A. Schock anticipates that the company will earn ($0.12) per share for the quarter. B. Riley has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Exagen's Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.09) EPS.

A number of other equities research analysts also recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $10.00 price objective on shares of Exagen in a research report on Wednesday, July 30th. KeyCorp raised shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price objective on the stock in a research report on Wednesday, July 30th. Canaccord Genuity Group increased their price objective on shares of Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Wednesday, July 30th. Finally, Craig Hallum started coverage on shares of Exagen in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $12.00.

Exagen Stock Down 0.9%

Shares of NASDAQ:XGN traded down $0.09 during trading hours on Monday, reaching $9.56. The stock had a trading volume of 331,626 shares, compared to its average volume of 186,242. Exagen has a 1 year low of $2.38 and a 1 year high of $10.34. The firm's 50 day moving average is $8.94 and its 200-day moving average is $6.77. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95. The stock has a market capitalization of $210.32 million, a price-to-earnings ratio of -10.74 and a beta of 1.60.

Exagen (NASDAQ:XGN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen has set its FY 2025 guidance at EPS.

Institutional Trading of Exagen

A number of large investors have recently bought and sold shares of XGN. Acadian Asset Management LLC acquired a new stake in Exagen during the 1st quarter worth $25,000. Northern Trust Corp boosted its stake in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after purchasing an additional 2,630 shares during the period. XTX Topco Ltd acquired a new stake in Exagen during the 2nd quarter worth $133,000. Occudo Quantitative Strategies LP acquired a new stake in Exagen during the 2nd quarter worth $138,000. Finally, Bridgeway Capital Management LLC boosted its stake in Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company's stock worth $194,000 after purchasing an additional 2,600 shares during the period. Institutional investors and hedge funds own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).